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Central serous chorioretinopathy (CSC) is one of the 
several chorioretinal disorders characterized by serous 
detachment of the neurosensory retina and/or the retinal 
pigment epithelium (RPE). CSC occurs most frequently 
in middle-aged men. Major symptoms are blurred vision, 
usually in one eye only and perceived typically by the 
patient as a dark spot in the center of the visual field with 
associated micropsia and metamorphopsia. Normal vision 
often recurs spontaneously within a few months. The con-
dition can be precipitated by psychosocial stress [1].
Resolution of detachment can usually be achieved in 
80% to 90% of acute CSC spontaneously within 3 months. 
In acute stage, observation is usually the first proposed 
treatment option. In recurrent or persistent detachment, 
which is often associated with more diffuse RPE change, 
however, laser photocoagulation of RPE leakage site(s) 
is also recommended. It can hasten resolution of associ-
ated serous macular detachment, shortens the duration of 
the disease and reduces the recurrence rate. Nonetheless, 
this treatment modality is not without risk. It may cause 
permanent scotoma which may enlarge over time with 
RPE scar expansion as well as choroidal neovasculariza-
tion (CNV) development [2,3]. There are also a few reports 
about beneficial effect of photodynamic therapy (PDT) in 
chronic CSC. However, it is expensive and cases of CNV 
have been reported following this treatment [4-6]. 
Anti-vascular endothelial growth factors, through their 
anti-permeability characteristics and hence leakage reduc-
tion, may be useful in the treatment of cases with refrac-
tory CSC and may be helpful as an alternative manage-
ment. Recently, there are a few case reports with limited 
number of patients evaluating the effect of intravitreal 
bevacizumab for treatment of refractory CSC [7-9]. Nev-
ertheless, the literature still suffers from lack of sufficient 
data in this field. Performing another case series, we also 
tried to assess the effect of single injection of intravitreal 
bevacizumab for treatment of refractory CSC.
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In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more 
than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a 
through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual 
acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence 
tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 ± 0.25 to 0.50 ± 0.18 and 0.29 ± 0.19 
logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also 
decreased significantly (p = 0.010) from 370 ± 65 to 208 ± 23 µm at 4 months. No recurrence was occurred 
during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.
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This prospective interventional case series was approved 
by the review board/ethics committee of the Ophthalmic 
Research Center of the university. An informed consent 
was obtained from each patient.
Five eyes of 5 patients with diagnosis of refractory CSC 
(lasting more than 1 year) were included in this study. 
Diagnosis was made by the history of recurrent blurred 
vision and metamorphopsia for more than one year, detec-
tion of neurosensory detachment in ophthalmoscopy and 
optical coherence tomography (OCT), and observation of 
active RPE leakage in flourscein angiography. Exclusion 
criteria consisted of any accompanying macular disease, 
severe media haziness which precludes OCT evaluation, 
and noncompliance. Each participant underwent a thor-
ough ophthalmic examination.
All eyes received a single injection of 0.05 mL (1.25 mg) 
intravitreal bevacizumab (Avastin; Genentech Inc., South 
San Francisco, CA, USA [made for F. Haffmann-La Roche 
Ltd., Basel, Switzerland]) performed by a 30-guage needle 
through supratemporal quadrant 4 mm from the limbus 
under sterile condition. 
All patients underwent a through ophthalmic examina-
tion 1 day, 1 week, and 1, 2, and 6 months after the injec-
tion. Best corrected visual acuity (BCVA) of the eyes was 
checked by a masked optometrist. It was changed to the 
logarithm of minimum angle of resolution (logMAR) scale 
for statistical purposes and compared at months 2 and 6 
with the baseline values. Central macular thickness (CMT) 
measured by OCT (3D OCT-1000; Topcon Corporation, 
Tokyo, Japan) was performed at presentation and repeated 
6 months after the intervention. It was measured in a 
1-mm circle centered on the fovea by an optician who was 
masked to the study. The data were analyzed by paired t-
test. Statistical level of significance was preset at 0.05.  
The initial characteristics are listed in Table 1. None of 
the patients had history of intraocular surgery, diabetes 
mellitus, hypertension, cardiovascular disease and smok-
ing. An increase of BCVA was noticed during the follow-
up in all eyes except case 1. Mean BCVA at baseline was 
0.60 ± 0.25 that improved to 0.42 ± 0.16 and 0.24 ± 0.21 
logMAR up to the month 2 and 6, respectively. This im-
provement at 2 months did not reach to a meaningful level 
(p = 0.064); however, it was statistically significant at 6 
months (p = 0.025). No recurrence was observed in any 
of the eyes during the follow-up period. Central macular 
thickness decreased significantly from 370 ± 65 µm at 
baseline to 210 ± 24 µm at 6 months after injections (p = 
0.009) (Table 2). Figure 1 demonstrates the OCT pictures 
of 4 cases before and after treatment. No major ocular or 
systemic complication was encountered in this study. None 
of the eyes had intraocular pressure rise (>21 mmHg) or 
cataract progression during the follow-up period. 
Discussion
Various medications have been suggested for the treat-
ment of CSC by different authors. They include acetazol-
amide, beta-blockers, vitamins, and non-steroidal anti-
inflammatory drugs. None of them has been proved to be 
beneficial. On the other hand, there are some controversial 
recommendations in the literature on the use of laser pho-
tocoagulation in this field. Some authors reporting that la-
ser photocoagulation shortens the duration of disease and 
reduces recurrence rate, while others maintain that it does 
not affect final vision and recurrence rate. Furthermore, la-
ser may be associated with permanent scotoma which may 
enlarge over time with RPE scar expansion, as the possible 
development of CNV [2,3].
Table 1. Initial characteristics of the cases
Case 1 Case 2 Case 3 Case 4 Case 5
Sex Male Male Male Male Female
Age (yr)    36   47   40   36   39
Laterality Left Left Left Left Right
Duration of symptoms (yr)   6    2    2    1    3 
No. of attacks   4   5   3   2   2
Previous fellow eye involvement - - + + -
Table 2. Best corrected visual acuity and central macular thickness changes during follow-up
Case 1 Case 2 Case 3 Case 4 Case 5
Visual acuity (logMAR) Before  0.4 0.7 0.4 0.5 1.0
Month 2 0.4 0.3 0.3 0.4 0.7
Month 6 0.5 0.1 0.0 0.2 0.5
Central macular thickness (μm) Before  380 378  461  280  350
Month 6 224 238 189 224  182 141
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Photodynamic therapy has also been attempted with 
some success for treatment of refractory CSC. It may has-
ten resolution of exudation by reducing choroidal blood 
flow and hence favoring cessation of leakage [10]. Most 
recently, several case series have reported the use of in-
docyanine green guided PDT in the treatment of chronic 
CSC [11]. Ober et al. [12] reported the successful treatment 
of focal RPE leaks in CSC by PDT in a small pilot series 
which showed resolution and visual improvement. Cardillo 
Piccolino et al. [6] performed indocyanine green guided 
PDT in 16 eyes with chronic CSC and treatment resulted in 
complete resolution of serous retinal detachment 1 month 
after treatment in 75% of eyes. At 3 months after PDT, 
69% of eyes had visual improvement of 1 or more lines. 
However, 31% of their cases developed secondary RPE 
changes at the site of PDT, which were thought to be due 
to hypoxic damage caused by choriocapillaris occlusion. 
Moreover, PDT is an expensive treatment and may cause 
CNV formation [13].
Our study showed a significant visual improvement and 
CMT reduction following single injection of IVB (1.25 mg) 
in 5 cases suffering from refractory CSC for more than 
one year. In a similar study on 5 cases with CSC, Torres-
Soriano et al. noticed an improvement in BCVA, fluores-
cein angiographic leakage, and reduced or resolved neuro-
sensory detachment. However, they injected 2.5 mg IVB 
and included cases with history of decreased visual acuity 
more than 3 months, recurrent episodes of CSC or even 
acute cases with excessive discomfort about visual acuity 
[7].
In a case series on 12 eyes, Schaal et al. [9] showed that 
in cases with chronic CSC IVB injection improved BCVA 
and reduced CMT. However, they performed multiple in-
jections of 2.5 mg IVB at 6 to 8 week intervals (range, 1 to 
4 weeks). However, recurrence did not occur in any case of 
our study during follow up period.
In summery, the present study demonstrated a promis-
ing effect of IVB in the treatment of refractory CSC; how-
ever, we can not make specific treatment recommendations 
based on this small, uncontrolled case series. Further clini-
cal trials with control group are warranted. Further studies 
with large sample size are warranted.
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